Navigation Links
Childers, Schlueter & Smith, LLC Set for Reglan/metoclopramide Jury Trial Involving Woman's Development of Tardive Dyskinesia
Date:7/19/2010

ATLANTA, July 19 /PRNewswire/ -- The law firm of Childers, Schlueter & Smith, LLC of Atlanta, Georgia has announced that a jury trial involving the drug Reglan/metoclopramide will be held during the week of July 26, 2010.  The case is Susan Swicegood v. Pliva et. al. in the United States District Court, Northern District of Georgia, Atlanta Division.

The lawsuit alleges that the drug makers and marketers of Reglan/metoclopramide failed to adequately warn physicians of the long-term dangers associated with taking the drug, specifically, the neurological disorder tardive dyskinesia.

Reglan and its generic equivalent, metoclopramide, are used to treat several types of stomach disorders including nausea and acid reflux. The complaint alleges that Ms. Swicegood's doctor prescribed 10mg Reglan to be taken four times daily. Ms. Swicegood took the generic form of the drug and developed a permanent movement disorder called tardive dyskinesia as a result - a disorder of the nerves in which involuntary, repetitive movements develop in the lower portion of the face and in limbs.

Previous and Pending Reglan lawsuits, which now total over 150 filed, prompted the FDA to change requirements in the labeling of the drug in February 2009 to account for the increased risk of developing tardive dyskinesia from Reglan/metoclopramide use. New rules included a "Black Box" warning about the potential risk of tardive dyskinesia from long-term use. However, the suit alleges that the Physician's Desk Reference used by Ms. Swicegood's doctor was not updated with the new warnings as required by law.  As a result, neither the patient nor her doctor understood the true risk of taking or prescribing the drug.

The lawsuit was filed in the United States District Court, Northern District of Georgia, Atlanta Division. The Defendant in the case is Pliva, Inc. The Civil Action File Number is 1:07-CV-1671. Childers, Schlueter & Smith, LLC will conduct the Reglan/metoclopramide jury trial with its nationally renowned co-counsel of Daniel J. McGlynn of McGlynn, Glisson, and Mouton Law Firm and Bill Curtis of Miller, Curtis & Weisbrod, LLP.

About Childers, Schlueter & Smith:

Childers, Schlueter & Smith is a preeminent Georgia law firm that takes pride in years of experience and exceptional results. For more about the alleged dangers of Reglan/metoclopramide, or to learn more about Childers, Schlueter & Smith, call toll free at 1-800-641-0098 or visit http://www.cssfirm.com.


'/>"/>
SOURCE Childers, Schlueter & Smith, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
2. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
3. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
4. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
5. Robbins & Myers Announces Regular Quarterly Cash Dividend
6. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
7. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
8. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
9. Robbins & Myers Announces Fourth Quarter and Full Year 2009 Results
10. Dynatronics Appoints Douglas Sampson as Vice President of Production and Research & Development
11. Frost & Sullivan Identifies Focus on Quality Management and Adoption of a Full-service Model as Keys to the Growth of the European CRO Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 27, 2016   ... in Recurring Consumable Sales  Clinical sales grow ... Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the ... for the first quarter ended March 31, 2016 and ... of its commercial strategy. First Quarter 2016 ...
(Date:4/27/2016)... , April 27, 2016  Bayer Animal Health ... senior from the University of Florida College of ... Bayer Excellence in Communication Award (BECA). Brittany was ... were awarded a total of $70,000 in scholarship ... four years, Bayer has provided a total of ...
(Date:4/27/2016)... FRANCISCO , April 27, 2016 ... expected to reach USD 2.06 billion by 2022, ... Research, Inc. Increasing consumer awareness towards a healthy ... the next seven years.      (Logo: ... diet intake coupled with rising health treatment expenditure ...
Breaking Medicine Technology:
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... In ... a mother and divorcee, shares her enthusiasm for Botox and lip injections, which she ... world famous youth oriented Coachella Valley Music and Arts Festival. The article explains that ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... by the Accreditation Council for Graduate Medical Education (ACGME) that it has received ... is the first accreditation of three residency programs that Memorial is currently pursuing, ...
(Date:4/29/2016)... ... ... Our bodies are bombarded daily by environmental and lifestyle factors that can ... to adopt a more healthful diet, but too many people think that food has ... and the creator of the Newport Beach Cleanse and 14-Day Eating Plan, disagrees whole-heartedly. ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce is ... even security. Most importantly, employees are the single most important asset in creating ... so unhappy? , Just under half of American workers are emotionally checked out ...
(Date:4/29/2016)... ... April 29, 2016 , ... The ... in repaying their loans, more information about their loan terms and accounts, and ... student loan debt, including federal and private loans, has reached $1.3 trillion, with ...
Breaking Medicine News(10 mins):